trial

Open Label Extension Study of Bifeprunox

NCTId NCT00366171
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 120
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
120
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2006-11
Primary completion
—
Eligibility
ALL · 18 Years · 66 Years

Interventions & indications

Drugs
Bifeprunox

Sponsors

Wyeth is now a wholly owned subsidiary of PfizerLead Sponsor

Sites

0 total

Facts & assertions

3 sourced
Enrollment
120
Phase
PHASE3
Status
COMPLETED
relationships
The graph out of here
drug
Bifeprunox
drug
lead_sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
company
indication
Schizophrenia
indication
Schizophrenia
indication